SFRP2 and triple-negative breast carcinoma: Our laboratory previously reported the development of a hSFRP2 mAb that binds to SFRP2 with high affinity, is well tolerated and is efficacious at inhibiting human triple-negative breast cancer and murine angiosarcoma growth in vivo [10].